The Centers for Medicare and Medicaid Services is not ready to reconsider its national coverage determination that conditions Medicare reimbursement for amyloid-directed Alzheimer’s drugs on use within a study, the agency told the Alzheimer’s Association.
The clinical benefit of a promising drug in the class, Eisai Co., Ltd./Biogen, Inc